Dr. Benjamini earned his medical degree in 2002 from Semmelweis University, Budapest Hungary and completed his residency in Internal Medicine at Meir Medical Center, Israel and Hematology fellowship in the Department of Hematology and Bone Marrow Transplantation at Chaim Sheba Medical Center.
In 2012 he enrolled in the Leukemia fellowship at the Department of Leukemia at MD Anderson Cancer Center, Huston, Texas, with main focus on Chronic Lymphocytic Leukemia. He gained his clinical expertise in the field of CLL under the guidance of Prof. Keating at the era of emergence of the novel therapies in CLL and conducted clinical research on second malignancies after FCR therapy and the treatment options and responses of high risk CLL patients who relapsed after Allogeneic Stem Cell Transplantation.
Back in Israel since 2014 he is running the CLL program in Chaim Sheba Medical Center. The field CLL is undergoing an incredible breakthrough with highly effective, novel, non-chemotheapy agents. As a Principal Investigator in clinical trials in the field of CLL Dr Benjamini ‘s goal is to make novel effective therapy accessible to every patient including patients from abroad.
- Senior Specialist and Principal investigator in clinical trials in CLL at Hematooncology Department
Conditions and treatment
- Chronic Lymphocytic leukemia
- Non Hodgkin’s Lymphoma
- Hodgkin’s Lymphoma
- Lymphoproliferative diseases
- Benign hematology
Education and Training
- Semmelweis University, Budapest Hungary
- Residency in internal medicine at Meir Medical Center
- Fellowship in the department of hematology and bone marrow transplantation at Chaim Sheba Medical Center
- Fellowship at the department of leukemia at MD Anderson cancer center, Huston Texas
- Internal medicine
- Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA). Jain P, Konoplev S, Benjamini O, Romagura J, Burger JA.
- Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. Davidson T, Priel E, Schiby G, Raskin S, Chikman B, Nissan E, Benjamini O, Nissan J, Goshen E, Ben-Haim S, Salomon O, Avigdor A.
- The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Avigdor A, Benjamini O, Nagler A, Pereg Y, Tavor S, Peled A.